<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230701058628N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-27</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of effectiveness of dexmedetomidine plus Midazolam and fentanyl plus Midazolam in placement of central venous catheter in PICU</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of effectiveness of dexmedetomidine plus Midazolam and fentanyl plus Midazolam in placement of central venous catheter in Pediatric Intensive Care Unit (PICU)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71340</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: After meeting the inclusion criteria for the study, randomization is done by simple randomization method with age block. Dexmedetomidine and fentanyl drugs are similarly prepared and coded in a 10 mL syringe by a pharmacist and provided to the researcher. The patient and the treatment team will not know the nature of the contents of the syringes, and the desired syringe will be delivered to the treatment team daily based on the initial group determined. Only at the end of the study or in case of a complication that requires therapeutic intervention and knowing the name of the drug, the drug code is decoded by the researcher and the name of the drug is provided to the doctor. Before assigning the individuals in groupa, the assigned group is not clear, Blinding description: The study will be conducted in a double-blind manner. Dexmedetomidine and fentanyl drugs are similarly prepared and coded in a 10 mL syringe by a pharmacist and kept in the refrigerator until use. The patient, the prescribing nurse and the doctor are not aware of the type of therapeutic combination used. Only at the end of the study or in case of a complication that requires therapeutic intervention and knowing the name of the drug, the drug code is decoded by the researcher and the name of the drug is provided to the doctor.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Viral infection. Condition 2: Acute lower respiratory infection. Condition 3: Virus infections of central nervous system. Condition 4: Immunodeficiency. Condition 5: Renal failure requiring dialysis or plasmaphresis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, 1 μg/kg intravenous dexmedetomidine is prescribed for ten minutes along with 0.1 mg/kg injectable midazolam as a loading dose. Dexmedetomidine infusion continues at a rate of 1 μg/kg/hour. Intervention 2: Control group: The control group recieves the general protocol of the Pediatric Intensive Care Unit (PICU) of BuAli Hospital and for sedation, receives fentanyl at a dose of 1 μg/kg for 10 minutes along with midazolam at a dose of 0.1 mg/kg during the procedure. Fentanyl infusion continues at a rate of 1 μg/kg/h.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Contact Dr.Mohammad Reza Navaeifar. Email: dr.navaifar@gmail.com

When:
Informations will send within few days after the email

To whom:
People working in academic institutions

Conditions:
Contact Dr.Mohammad Reza Navaeifar. Email: dr.navaifar@gmail.com

Where to obtain:
Email

How to obtain:
Informations will send within few days after the email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Fahimeh Dianati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pediatric Infectious Diseases Research Center, Buali Hospital, Pasdaran Boulevard, Sari, Iran</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815838477</zip>
        <telephone>+98 11 3334 2334</telephone>
        <email>pidrc@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Reza Navaeifar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pediatric Infectious Diseases Research Center, Buali Hospital, Pasdaran Boulevard, Sari, Iran</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815838477</zip>
        <telephone>+98 11 3334 2334</telephone>
        <email>m.navaeifar@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children needing central venous catheter placement in the pediatric intensive care unit</inclusion_criteria>
      <agemin>1 month</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Presence of bradycardia or hypotension
High blood pressure above the 99th percentile
Apnea before the study
The presence of cardiac conduction disorder in the electrocardiogram before drug administration
Patients with American Society of Anaesthesiologists' physical status classification III or higher
Known kidney or heart failure
History of heart surgery
Shock
Receiving other anesthetics, sedatives, injectable painkillers</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B34</hc_code>
      <hc_code>J22</hc_code>
      <hc_code>A81</hc_code>
      <hc_code>D84.9</hc_code>
      <hc_code>P96.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Viral infection of unspecified site</hc_keyword>
      <hc_keyword>Unspecified acute lower respiratory infection</hc_keyword>
      <hc_keyword>Atypical virus infections of central nervous system</hc_keyword>
      <hc_keyword>Immunodeficiency, unspecified</hc_keyword>
      <hc_keyword>Congenital renal failure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, 1 μg/kg intravenous dexmedetomidine is prescribed for ten minutes along with 0.1 mg/kg injectable midazolam as a loading dose. Dexmedetomidine infusion continues at a rate of 1 μg/kg/hour.</i_keyword>
      <i_keyword>Control group: The control group recieves the general protocol of the Pediatric Intensive Care Unit (PICU) of BuAli Hospital and for sedation, receives fentanyl at a dose of 1 μg/kg for 10 minutes along with midazolam at a dose of 0.1 mg/kg during the procedure. Fentanyl infusion continues at a rate of 1 μg/kg/h.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Ramsay Sedation Score equal to or more than 3. Timepoint: Every 5 minutes until 5 minutes after sedation. Method of measurement: Ramsay scale.</prim_outcome>
      <prim_outcome>Mean arterial blood pressure. Timepoint: Every 5 minutes until 5 minutes after sedation. Method of measurement: Blood pressure monitor.</prim_outcome>
      <prim_outcome>Blood oxygen saturation. Timepoint: Every 5 minutes until 5 minutes after sedation. Method of measurement: Palsoxymeter.</prim_outcome>
      <prim_outcome>Heart rate and respiratory rate. Timepoint: Every 5 minutes until 5 minutes after sedation. Method of measurement: تعداد در دقیقه.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-24</approval_date>
        <contact_name>Ethics committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Pediatric Infectious Diseases Research Center, Buali Hospital, Pasdaran Boulevard, Sari, Iran Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
